Enveric Biosciences (ENVB) Dividends payables (2017 - 2020)
Enveric Biosciences (ENVB) posted Dividends payables of $645425.0 for Q3 2020, up 20.42% sequentially from $535968.0 in Q2 2020, and up 203.02% YoY from $212999.0 in Q4 2019.
Enveric Biosciences (ENVB) Dividends payables (2017 - 2020) Analysis & Trends
Enveric Biosciences has reported Dividends payables for 4 years, with the latest figure at $645425.0 in Q3 2020.
- Quarterly Dividends payables rose 203.02% year-over-year to $645425.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $645425.0 (up 203.02% YoY) and the FY2019 annual result came in at $320298.0, up 204.52% from the prior year.
- Dividends payables rose to $645425.0 in Q3 2020 per ENVB's latest filing, from $535968.0 in the prior quarter.
- Over five years, Dividends payables peaked at $661553.0 in Q2 2018 and troughed at $104657.0 in Q3 2018.
- A 4-year average of $386904.3 and a median of $464049.0 in 2017 frame the typical range for Dividends payables.
- The sharpest annual moves came in 2019 and 2020: Dividends payables sank 83.94% in 2019, then jumped 404.52% in 2020.
- Over 4 years, Dividends payables stood at $527979.0 in 2017, then plunged by 80.08% to $105181.0 in 2018, then soared by 204.52% to $320298.0 in 2019, then soared by 101.51% to $645425.0 in 2020.
- According to Business Quant data, Dividends payables over the past three periods registered $645425.0, $535968.0, and $428133.0 for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 645,425.00 |
| Jun 30, 2020 | 535,968.00 |
| Mar 31, 2020 | 428,133.00 |
| Dec 31, 2019 | 320,298.00 |
| Sep 30, 2019 | 212,999.00 |
| Jun 30, 2019 | 106,234.00 |
| Mar 31, 2019 | 210,886.00 |
| Dec 31, 2018 | 105,181.00 |
| Sep 30, 2018 | 104,657.00 |
| Jun 30, 2018 | 661,553.00 |
| Mar 31, 2018 | 557,417.00 |
| Sep 30, 2017 | 527,979.00 |
| Jun 30, 2017 | 499,965.00 |
| Mar 31, 2017 | 499,965.00 |